RT Journal Article
T1 Dermatological adverse reactions after vaccination with BNT162b2 in a cohort of healthcare workers.
A1 Ruiz-Villaverde, Ricardo
A1 Rivera-Izquierdo, Mario
A1 Gil-Villalba, Ana
A1 Pegalajar-Garcia, Maria D
A1 Perez-Rojas, Javier
A1 Soler-Iborte, Eva
A1 Valero-Ubierna, M Carmen
K1 Análisis multivariante
K1 Dermatología
K1 Exantema
K1 Infecciones
AB The description of the skin reactions produced by the different vaccines against SARS-CoV-2 has focused on the symptoms reported by the general population. There are few studies with very different measurement methods focused on healthcare workers. A longitudinal observational study was conducted on all the healthcare workers from the Hospital Universitario San Cecilio that received vaccination against COVID-19 with BNT162b2. The recruitment period was from December 2020 to September 2021. The recommended regimen was double, with a minimum interval of 21 days between doses. All dermatological reactions reported as adverse effects of the vaccine were evaluated by the Staff of the Dermatology Unit of our center. A total of 3969 healthcare workers of our center were followed. Only 0.7% of them reported dermatological adverse reactions. The most frequently reported reactions were morbilliform rash and COVID arm. In the multivariate analysis, the vaccination regimen (one dose) and the history of COVID-19 infection remained the main factors associated with the report of dermatological adverse reactions. The rate of dermatological adverse reactions after vaccination with BNT162b2 (Pfizer-BioNTech) is extraordinarily low. No patient required hospitalization, which supports the safety of this vaccination in a population of healthcare workers.
YR 2022
FD 2022-06-15
LK http://hdl.handle.net/10668/19967
UL http://hdl.handle.net/10668/19967
LA en
NO Ruiz‐Villaverde R, Rivera‐Izquierdo M, Gil‐Villalba A, Pegalajar‐García MD, Pérez‐Rojas J, Soler‐Iborte E, et al. Dermatological adverse reactions after vaccination with BNT162b2 in a cohort of healthcare workers. International Journal Of Dermatology. 30 de junio de 2022;61(10):1289-93
DS RISalud
RD Apr 16, 2025